Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) EBT: 2014-2024

Historic EBT for Rocket Pharmaceuticals (RCKT) over the last 11 years, with Dec 2024 value amounting to -$266.8 million.

  • Rocket Pharmaceuticals' EBT rose 24.15% to -$52.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$248.2 million, marking a year-over-year increase of 7.45%. This contributed to the annual value of -$266.8 million for FY2024, which is 4.13% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its EBT stood at -$266.8 million for FY2024, which was down 4.13% from -$256.2 million recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' EBT ranged from a high of -$139.1 million in FY2020 and a low of -$266.8 million during FY2024.
  • In the last 3 years, Rocket Pharmaceuticals' EBT had a median value of -$256.2 million in 2023 and averaged -$248.5 million.
  • Data for Rocket Pharmaceuticals' EBT shows a maximum YoY tumbled of 76.78% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Rocket Pharmaceuticals' EBT stood at -$139.1 million in 2020, then dropped by 20.15% to -$167.2 million in 2021, then slumped by 33.00% to -$222.3 million in 2022, then decreased by 15.26% to -$256.2 million in 2023, then dropped by 4.13% to -$266.8 million in 2024.